Company profile for Tolmar

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Tolmar, science drives everything we do. Through a relentless focus on technology, science, partnership and excellence, we seek to advance patient care and deliver value through innovative therapies and services. The Tolmar portfolio includes specialty products for urology, oncology and dermatology. The invention, development and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) delivers innovat...
At Tolmar, science drives everything we do. Through a relentless focus on technology, science, partnership and excellence, we seek to advance patient care and deliver value through innovative therapies and services. The Tolmar portfolio includes specialty products for urology, oncology and dermatology. The invention, development and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) delivers innovation and commitment to the urology, oncology and hospital communities, providers and patients. Technology-driven development and high-quality manufacturing capabilities established Tolmar.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
701 Centre Ave, Fort Collins, CO 80526
Telephone
Telephone
970-212-4500
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/tolmar-collaborates-with-direct-to-patient-telemedicine-company-upscripthealth-to-increase-access-to-oral-testosterone-replacement-therapy-302283766.html

PR NEWSWIRE
23 Oct 2024

https://www.prnewswire.com/news-releases/the-pharma-group-enters-into-an-exclusive-promotional-agreement-with-tolmar-inc-to-promote-rubraca-rucaparib-in-the-us-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer-302256330.html

PR NEWSWIRE
24 Sep 2024

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-4-2023-22726.pdf

FDA
04 Oct 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211995

FDA
30 Jun 2023

https://www.prnewswire.com/news-releases/tolmar-announces-acquisition-of-jatenzo-testosterone-undecanoate-for-the-treatment-of-hypogonadism-to-expand-its-market-leading-urology-portfolio-301662003.html

PRNEWSWIRE
27 Oct 2022

https://www.globenewswire.com/news-release/2022/10/18/2536906/19989/en/Clarus-Therapeutics-Holdings-Inc-Announces-Completion-of-Auction-for-Sale-of-JATENZO-and-Selection-of-Tolmar-Inc-as-Successful-Bidder.html

GLOBENEWSWIRE
18 Oct 2022

Excipients

Click here to find the perfect excipient manufacturers by their capabilities

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty